<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410694</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_MM-1</org_study_id>
    <nct_id>NCT02410694</nct_id>
  </id_info>
  <brief_title>Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
  <official_title>Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overview of Study Design:&#xD;
&#xD;
      This is an open phase II, single-arm, multi-center study to evaluate progression free&#xD;
      survival in patients receiving ixazomib in combination with thalidomide and dexamethasone&#xD;
      (ITD) followed by an ixazomib maintenance phase of a maximum period of 12 months.&#xD;
&#xD;
      The patient population will consist of adult male and female patients with multiple myeloma&#xD;
      (MM) with relapsed and/or refractory disease after at least one prior treatment line.&#xD;
&#xD;
      In case of enrollment patients will receive ixazomib 4.0mg at days 1, 8, 15, thalidomide&#xD;
      100mg at days 1 to 28 (50mg in patients aged ≥75 years), and dexamethasone 40mg (20mg in&#xD;
      patients aged ≥75 years) at days 1, 8, 15 of a 28-day treatment cycle. The proposed number of&#xD;
      cycles is 8. Treatment will be discontinued in case of progressive disease or in case of no&#xD;
      response after 4 cycles (≤ SD after 4 cycles). After discontinuation of therapy an end of&#xD;
      treatment visit (EOT) will be performed within 14 days after the last dose of the last&#xD;
      combination treatment cycle.&#xD;
&#xD;
      After 8 cycles of ITD therapy, maintenance treatment with 4.0mg ixazomib (3.0mg in patients&#xD;
      aged ≥ 75 years at first day of maintenance phase) on days 1, 8, 15 of 28-day cycles will be&#xD;
      administered to patients with ≥ MR for a maximum period of 12 months. Patients who completed&#xD;
      less than 8 cycles of ITD treatment do not qualify for maintenance phase.&#xD;
&#xD;
      Follow-up visits will be performed in 3-monthly intervals until the last patient on ixazomib&#xD;
      maintenance therapy has concluded or discontinued the maintenance phase.&#xD;
&#xD;
      A safety analysis will be conducted after enrollment of the first 6 patients and completion&#xD;
      of at least two cycles in every patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">May 2, 2019</completion_date>
  <primary_completion_date type="Actual">March 28, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>start of combination therapy to progressive disease or death due to any cause whichever occurs first, up to 4.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>best and first response since start of therapy, up to 4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>start of therapy to death, up to 4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Response in a subgroup of patients with baseline GFR 15-30ml/min</measure>
    <time_frame>start of therapy to best renal response, up to 4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of safety by reporting of adverse events</measure>
    <time_frame>start of therapy to end of study therapy (appr. 2 yrs)</time_frame>
    <description>Reporting of adverse event as a measure of safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of prognostic values of risk factors at diagnosis incl. clinical assessment and cytogenetic abnormalities</measure>
    <time_frame>screening to end of study (appr. 2 yrs)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between altered expressions of specifically selected genes and patient´s response to the treatment regimen</measure>
    <time_frame>screening to end of study (appr. 2 yrs)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Ixazomib-Thalidomide-Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy of:&#xD;
Ixazomib 4.0mg at days 1, 8, 15, Thalidomide 100mg at days 1 to 28 (50mg in patients aged ≥75 years), Dexamethasone 40mg (20mg in patients aged ≥75 years) at days 1, 8, 15 of a 28-day treatment cycle.&#xD;
After 8 cycles of ITD therapy, maintenance treatment with 4.0mg ixazomib (3.0mg in patients aged ≥ 75 years at first day of maintenance phase) on days 1, 8, 15 of 28-day cycles will be administered to patients with ≥ MR for a maximum period of 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib</intervention_name>
    <arm_group_label>Ixazomib-Thalidomide-Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <arm_group_label>Ixazomib-Thalidomide-Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Ixazomib-Thalidomide-Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients 18 yrs or older.&#xD;
&#xD;
          2. Voluntary written consent&#xD;
&#xD;
          3. Patients in need of therapy with a diagnosis of relapsed or refractory multiple&#xD;
             myeloma who had at least one prior treatment line&#xD;
&#xD;
          4. Patients must have measurable disease defined by at least 1 of the following criteria:&#xD;
&#xD;
               -  Serum M-protein ≥ 10g/l&#xD;
&#xD;
               -  Urine M-protein ≥ 200mg/24h&#xD;
&#xD;
               -  Serum free light chain assay: involved serum light chain ≥ 10mg/dl provided that&#xD;
                  free light chain ration is abnormal&#xD;
&#xD;
          5. Life expectancy &gt; 3 months&#xD;
&#xD;
          6. ECOG (Eastern Cooperative Oncology Group) ≤ 2&#xD;
&#xD;
          7. • ANC ≥ 1.000/mm3 and platelet count ≥ 50.000/mm3&#xD;
&#xD;
               -  Total bilirubin ≤ 2 x ULN&#xD;
&#xD;
               -  ALT and AST ≤ 3 x ULN&#xD;
&#xD;
               -  GFR ≥ 15ml/min as calculated by cockroft-Gault equation&#xD;
&#xD;
          8. Female patients who:&#xD;
&#xD;
               -  Are older than 50 years and postmenopausal for at least 1 year before the&#xD;
                  screening visit, OR&#xD;
&#xD;
               -  Are surgically sterile, OR&#xD;
&#xD;
               -  If they are of childbearing potential, agree to practice 2 effective methods of&#xD;
                  contraception at the same time, from 4 weeks before starting study therapy&#xD;
                  through 90 days after the last dose of study drug, OR&#xD;
&#xD;
               -  Agree to practice true abstinence when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation,&#xD;
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods&#xD;
                  of contraception.)&#xD;
&#xD;
               -  Are informed and understand the possible consequences of the teratogenic&#xD;
                  potential of thalidomide&#xD;
&#xD;
               -  Male patients, even if surgically sterilized (i.e., status post-vasectomy), must&#xD;
                  agree to one of the following:&#xD;
&#xD;
               -  Agree to practice effective barrier contraception during the entire study&#xD;
                  treatment period and through 90 days after the last dose of study drug, OR&#xD;
&#xD;
               -  Agree to practice true abstinence when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence (e.g. calendar, ovulation,&#xD;
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods&#xD;
                  of contraception.)&#xD;
&#xD;
               -  Are informed and understand the possible consequences of the teratogenic&#xD;
                  potential of thalidomide&#xD;
&#xD;
          9. Disease free of prior malignancies for ≥ 2 years with exception of curatively treated&#xD;
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix&#xD;
             or breast if they have undergone complete resection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. lactating females or have a positive serum pregnancy test&#xD;
&#xD;
          2. Failure to have fully recovered (i.e., ≤ Grade 1 toxicity) from the reversible effects&#xD;
             of prior chemotherapy&#xD;
&#xD;
          3. Previous treatment with ixazomib&#xD;
&#xD;
          4. Previous treatment with bortezomib or thalidomide within the last 3 months prior to&#xD;
             baseline visit&#xD;
&#xD;
          5. Primary refractory to, or relapsing during, or within ≤ 6 weeks after end of treatment&#xD;
             with a proteasome inhibitor and/or thalidomide&#xD;
&#xD;
          6. Previous anti-cancer treatment within the last 21 days prior to baseline visit (cycle&#xD;
             1 / day 1), except corticosteroid therapy (40 - 160mg dexamethasone or corticosteroid&#xD;
             dose equivalent per month)&#xD;
&#xD;
          7. Major surgery within 14 days before enrollment&#xD;
&#xD;
          8. Radiotherapy within 14 days before enrollment. If the involved field is small, 7 days&#xD;
             will be considered a sufficient interval between treatment and administration of the&#xD;
             ixazomib.&#xD;
&#xD;
          9. Central nervous system involvement&#xD;
&#xD;
         10. Infection requiring systemic antibiotic therapy or other serious infection within 14&#xD;
             days before study enrollment&#xD;
&#xD;
         11. Evidence of current uncontrolled cardiovascular conditions&#xD;
&#xD;
         12. Systemic treatment, within 14 days before the first dose of ixazomib, with strong&#xD;
             inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of&#xD;
             CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole,&#xD;
             nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin,&#xD;
             carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort&#xD;
&#xD;
         13. Ongoing or active systemic infection, active hepatitis B or C virus infection, or&#xD;
             known human immunodeficiency virus (HIV) positive&#xD;
&#xD;
         14. Any serious medical or psychiatric illness that could, in the investigator's opinion,&#xD;
             potentially interfere with the completion of treatment according to this protocol&#xD;
&#xD;
         15. Known allergy to any of the study medications, their analogues, or excipients in the&#xD;
             various formulations of any agent&#xD;
&#xD;
         16. Known GI disease or GI procedure that could interfere with the oral absorption or&#xD;
             tolerance of ixazomib including difficulty swallowing&#xD;
&#xD;
         17. Diagnosed or treated for another malignancy within 2 years before study enrollment or&#xD;
             previously diagnosed with another malignancy and have any evidence of residual&#xD;
             disease. Patients with basal cell, squamous cell carcinoma of the skin, or carcinoma&#xD;
             &quot;in situ&quot; of the cervix or breast with are not excluded if they have undergone&#xD;
             complete resection&#xD;
&#xD;
         18. Patient has ≥ Grade 3 peripheral neuropathy or Grade 2 with pain on clinical&#xD;
             examination during the screening period&#xD;
&#xD;
         19. Participation in other interventional clinical trials, including those with other&#xD;
             investigational agents not included in this trial, within 30 days of the start of this&#xD;
             trial and throughout the duration of this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz Ludwig, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wilhelminenspital Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ordensklinikum, KH der Barmherzigen Schwestern Linz, Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH der Elisabethinen Linz, 1. Interne Abteilung</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen, IV. Interne Abteilung</name>
      <address>
        <city>Wels</city>
        <state>Oberösterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik Graz, Klinische Abteilung für Hämatologie</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK Innsbruck, Universitätsklinik für Innere Medizin, Klinische Abteilung für Hämatologie und Onkologie</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.ö. BK Kufstein, Abteilung für Innere Medizin</name>
      <address>
        <city>Kufstein</city>
        <state>Tirol</state>
        <zip>6330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Feldkirch, Interne E</name>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <zip>6830</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Linz, Innere Medizin 3, Zentrum für Hämatologie und medizinische Onkologie</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik der PMU Universitätsklinik für Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH der Barmherzigen Brüder Wien, Innere Medizin</name>
      <address>
        <city>Wien</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Universität Wien, Universitätsklinik f. Innere Medizin I, Klin. Abt. f. Hämatologie u. Hämostaseologie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Brno and Faculty of Medicine MU Brno 2nd Internal Clinic</name>
      <address>
        <city>Brno</city>
        <zip>639 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Ostrava</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig - AöR Selbstständige Abteilung für Hämatologie, Internistische Onkologie und Hämostaseologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Innere Medizin II</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II Zentrum Innere Medizin</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

